Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrolife ABCHIX:VITRS -18.32%75 5-Year Yield-on-Cost % is 1.04 as of Aug. 03, 2026, which is 126% above its 10-year median of 0.46. GuruFocus rates CHIX:VITRS with a GF Score™ of 75/100 and a GF Value™ of kr185.92. The stock has 6 warning signs investors should review. Among 318 Medical Devices & Instruments companies, Vitrolife AB ranks worse than 69.5% on this metric.
Vitrolife AB's yield on cost for the quarter that ended in Jun. 2026 was 1.04.
The historical rank and industry rank for Vitrolife AB's 5-Year Yield-on-Cost % or its related term are showing as below:
CHIX:VITRs'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.14 Med: 0.46 Max: 1.29
Current: 1.04
During the past 13 years, Vitrolife AB's highest Yield on Cost was 1.29. The lowest was 0.14. And the median was 0.46.
CHIX:VITRs's 5-Year Yield-on-Cost % is ranked worse than 69.5% of 318
companies
in the Medical Devices & Instruments industry
Industry Median: 2.435
vs CHIX:VITRs: 1.04
Vitrolife AB (CHIX:VITRs) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Vitrolife AB 5-Year Yield-on-Cost % Related Terms
CHIX:VITRS vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Vitrolife AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Vitrolife AB is calculated as
Vitrolife AB (CHIX:VITRS) has a 5-Year Yield-on-Cost % of 1.04 as of Aug. 03, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Vitrolife AB and its competitors. This is 126% above median its historical median of 0.46. Over the past decade, Vitrolife AB's 5-Year Yield-on-Cost % has ranged from 0.14 to 1.29. According to the industry distribution chart, Vitrolife AB ranks #221 out of 318 companies in the Medical Devices & Instruments industry, placing it in the top 69.5%.
Is Vitrolife AB's 5-Year Yield-on-Cost % too high?
Vitrolife AB's current 5-Year Yield-on-Cost % of 1.04 is 126% above median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 1.29. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.44. Vitrolife AB's value of 1.04 is 57.3% below this industry median. Based on the distribution chart, Vitrolife AB ranks #221 out of 318 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Vitrolife AB has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #221 out of 318 companies for 5-Year Yield-on-Cost %. This places Vitrolife AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.44. Vitrolife AB's value of 1.04 is 57.3% below this benchmark. Historically, Vitrolife AB's own 5-Year Yield-on-Cost % has ranged from 0.14 to 1.29 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 2.44, Vitrolife AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.44, based on 318 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrolife AB's current 5-Year Yield-on-Cost % of 1.04 is 57.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current 5-Year Yield-on-Cost % is 1.04, which is 126% above median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Vitrolife AB (CHIX:VITRS) has a current 5-Year Yield-on-Cost % of 1.04. The stock's GF Value™ is kr185.92, compared to a current price of kr86.38 — trading 53.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.04, which is 126% above median its 10-year median of 0.46 and 57.3% below the Medical Devices & Instruments industry median of 2.44. Vitrolife AB's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current 5-Year Yield-on-Cost % is 1.04 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr86.38 is trading 53.5% below its estimated GF Value™ of kr185.92.
Key valuation signals for CHIX:VITRS:
5-Year Yield-on-Cost %: 1.04 (126% above median its 10-year median of 0.46)
GF Value™: kr185.92 vs. price of kr86.38 (53.5% below fair value)
Industry Position: 57.3% below the Medical Devices & Instruments median (#221 of 318)
No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
75GF Score
Get the complete analysis for CHIX:VITRS
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VITRS has been successfully added to your 
